International Association for the Study of Lung Cancer 2022 World Conference on Lung Cancer
Tagrisso plus savolitinib for EGFR+ NSCLC (AstraZeneca)
AstraZeneca announced the Phase 2 SAVANNAH, placebo-controlled trial of Tagrisso (osimertinib) plus savolitinib in patients with epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) with high levels of MET overexpression.
The objective response rate was 49% in EGFR mutated NSCLC patients. The ORR in patients with high MET levels who were not treated with prior chemotherapy was 52%. The ORR in patients without a high level of MET was 9%. Among all the patients, the ORR was 32%.
AstraZeneca is evaluating the combination in the Phase 3 SAFFRON trial.
Savolitinib is marketed as Orpathys in China and is commercialized by AstraZeneca and HUTCHMED. MET is the most common biomarker used in EGFR mutated patients who had resistance to targeted therapy.
For syndicate reports on pipeline intelligence, market access, and market research, please write to email@example.com